Alexander Drilon MD (@alexdrilon) 's Twitter Profile
Alexander Drilon MD

@alexdrilon

Chief, Early Drug Development Service; Associate Attending Physician, Thoracic Oncology Service; Memorial Sloan Kettering Cancer Center

ID: 389758857

linkhttps://www.mskcc.org/cancer-care/doctors/alexander-drilon calendar_today12-10-2011 23:21:19

171 Tweet

4,4K Followers

215 Following

Alexander Drilon MD (@alexdrilon) 's Twitter Profile Photo
Alexander Drilon MD
@alexdrilon

2 years ago

Breaking tradition can improve patient outcomes. In novel-known combinations where the novel drug is unlikely to work well alone, prolonged exposure to monotherapy in dose escalation is not patient-centric. This alternative FDA-approved phase I design poses a potential solution.

Breaking tradition can improve patient outcomes. In novel-known combinations where the novel drug is unlikely to work well alone, prolonged exposure to monotherapy in dose escalation is not patient-centric. This alternative FDA-approved phase I design poses a potential solution.